

Press Release

Basel, 30. June 2015

Accelerate Suspension-cell Screening and Combinatorial Profiling for Immunological Applications

IntelliCyt launches new iQue® Screener PLUS

iQue Screener PLUS is an integrated platform that delivers more choice and flexibility for high content analyses of single cells at the pace and price point that busy screening, immunology, and profiling labs demand.

IntelliCyt Corporation, a leading developer of integrated solutions that accelerate drug discovery and life science research, today announced the launch of the iQue® Screener PLUS. The iQue Screener platform is an integrated instrument, software, and reagent system that enhances the screening workflow from sample preparation through results. It enables rapid, high content, multiplexed analysis of cells and beads in suspension in 96, 384, and 1536 well plates. Due to its patented sample delivery system, plates are processed rapidly (less than 5 minutes for 96 wells) and assays can be miniaturized to conserve precious sample and use less reagent per well. Software-assisted automation, analysis, and experiment-level visualization tools reveal deep insight into complex biology through an easy-to-use, intuitive interface.



The iQue Screener PLUS was created in response to our customers who have a growing need to explore the complex biology of the immune response. It offers all of the cost saving and productivity benefits delivered by the iQue Screener platform, plus more choice and flexibility. It features 15 detection channels, including 13 fluorescence and 2 scatter detectors, which provide for richer content through higher order multiplexing.

„IntelliCyt’s technology has been successfully applied in antibody discovery, small molecule drug discovery, immune target screening and for combinatorial profiling in immuno-oncology and has been adopted by every top pharmaceutical company, many leading biotech companies and prestigious academic institutes.” said R. Terry Dunlay, CEO and Founder of IntelliCyt Corporation. “We believe the launch of the new iQue Screener PLUS will accelerate immunology and immunotherapy discovery research and enable scientists to develop novel and effective treatments for cancer and other serious diseases.”

Underneath the sleek exterior of the iQue Screener PLUS are high performance technologies designed to make it fast and capable, yet easy and enjoyable to use. By combining a powerful flow cytometry detection engine, with a novel and patented sample introduction mechanism, IntelliCyt has met throughput and content objectives in a way that no other suspension-cell-based screening platform can achieve.

Please contact us for detailed information!

Bucher Biotec AG
Viaduktstrasse 42
4051 Basel

Tel.: 061 269 1111

Email: info@bucher.ch
www: <http://www.bucher.ch>